Type 1 diabetes develops when the immune system gradually destroys the insulin-producing beta cells in the pancreas. This process unfolds over months to years, not overnight, and it typically begins long before any symptoms appear. By the time someone is diagnosed, they’ve already lost a significant portion of their beta cells. Understanding the stages of this process helps explain why researchers are now able to identify the disease years before it becomes clinical.
It Starts With Genetic Risk
More than 60 genes influence the risk of developing type 1 diabetes, but the most powerful ones belong to a family called HLA genes. These genes control how your immune system identifies threats. Specific variants of two HLA genes, known as DR and DQ, play the largest role. People who carry certain combinations of these variants have immune systems that are more likely to mistake beta cells for foreign invaders.
Not all variants carry equal risk. One high-risk combination (DR4-DQ8) increases the odds of developing type 1 diabetes roughly eightfold compared to the general population. Another (DR3-DQ2) increases risk about 3.5-fold. The highest risk of all belongs to people who inherit both of these combinations, one from each parent. On the other hand, a closely related variant (DR4-DQ7) is actually protective, with lower-than-average odds. The difference between these variants comes down to tiny molecular changes that alter how immune cells “read” proteins on beta cells.
Carrying high-risk genes doesn’t guarantee the disease. Most people with these variants never develop type 1 diabetes. Genetics loads the gun, but something else pulls the trigger.
Environmental Triggers That Set It Off
Researchers have long suspected that viral infections help initiate the autoimmune attack in genetically susceptible people. A group of common viruses called enteroviruses are the leading candidates. Beta cells have a specific receptor on their surface that enteroviruses can latch onto, and once inside, these viruses don’t always kill the cell outright. Instead, they can establish a low-grade, persistent infection.
This persistent infection changes the beta cell in ways that attract the immune system’s attention. The infected cell starts displaying viral proteins on its surface and sending out distress signals. In someone whose immune system is already primed by high-risk HLA genes to overreact, this can be enough to trigger a full autoimmune response. Researchers describe this as a “Trojan horse” mechanism: the virus sneaks in, and the immune system’s response to it ends up targeting the beta cell itself. Enteroviral vaccines are currently in development as a potential way to prevent this chain of events.
Other environmental factors under investigation include early childhood diet, the composition of gut bacteria, and the timing of certain infections. No single trigger has been proven to cause type 1 diabetes on its own. The current understanding is that it takes a combination of genetic susceptibility and one or more environmental exposures to get the process started.
The Immune System Turns on Beta Cells
Once the autoimmune process begins, the immune system produces proteins called autoantibodies that target specific components of beta cells. Four of these autoantibodies can be detected through blood tests: insulin autoantibodies, GAD autoantibodies, IA-2 autoantibodies, and ZnT8 autoantibodies. Each one targets a different protein found in or on beta cells.
The number of autoantibodies matters more than which specific ones are present. A person with two or more of these autoantibodies has a very high lifetime risk of eventually progressing to clinical diabetes. Someone with just one autoantibody has a much lower risk, and some people with a single autoantibody never progress at all. This is why screening programs test for multiple autoantibodies at once rather than relying on any single marker.
While autoantibodies are the measurable signal, they aren’t what actually destroys the beta cells. The real damage comes from immune cells, particularly a type of white blood cell called a T cell, that directly attacks and kills beta cells over time. The autoantibodies serve as evidence that this process is underway.
Three Stages Before and During Diagnosis
Researchers now divide type 1 diabetes development into three distinct stages, a framework that has changed how the disease is understood and monitored.
Stage 1 is defined by the presence of two or more autoantibodies with completely normal blood sugar levels. People in this stage feel fine and have no symptoms. Their beta cells are under attack, but enough remain functional to keep blood sugar in a healthy range. This stage can last for years.
Stage 2 is when blood sugar levels start to become abnormal. The person still has two or more autoantibodies, and they still have no noticeable symptoms, but lab tests reveal that their blood sugar regulation is slipping. This means enough beta cells have been destroyed that the remaining ones can no longer fully compensate. People in Stage 2 have a very high probability of progressing to clinical diabetes, often within a few years.
Stage 3 is the point of clinical diagnosis. By now, beta cell loss is significant enough that the body can no longer maintain blood sugar on its own. This is when the classic symptoms appear: excessive thirst, frequent urination, unexplained weight loss, fatigue, and blurred vision. Some people, especially young children, are first diagnosed during a dangerous condition called diabetic ketoacidosis, where the lack of insulin causes acids to build up in the blood.
How Long the Process Takes
The timeline from the first autoantibody appearing to a Stage 3 diagnosis varies enormously. In some children, the progression takes less than a year. In others, it stretches across a decade or more. Younger age at the time autoantibodies first appear tends to predict faster progression. The number of autoantibodies also matters: children who quickly develop three or four autoantibodies generally progress faster than those who stay at two for a long time.
This variability is one reason type 1 diabetes can appear at any age. While it’s most commonly diagnosed in children and teenagers, roughly half of all cases are diagnosed in adults. The autoimmune process in adult-onset cases may simply have a slower pace of beta cell destruction, allowing the remaining cells to compensate for years before finally tipping into clinical disease.
Screening and Early Intervention
Because the disease can now be identified years before symptoms, screening programs test at-risk individuals (primarily first-degree relatives of people with type 1 diabetes) for the four major autoantibodies through a simple blood draw. The American Diabetes Association recommends ongoing monitoring for anyone found to have multiple autoantibodies, including regular blood sugar testing to detect the transition from Stage 1 to Stage 2.
Early identification has a practical benefit beyond awareness. In 2022, the FDA approved the first treatment capable of delaying the onset of Stage 3 type 1 diabetes. In a clinical trial of 76 high-risk participants who had multiple autoantibodies and abnormal blood sugar (Stage 2), the treatment delayed clinical diagnosis by a median of two years. In the control group, 72% developed clinical diabetes during the study period, compared to 43% in the treated group. The median time to diagnosis was about 24 months without treatment and 48 months with it.
Two extra years without clinical diabetes means two fewer years of insulin injections, blood sugar monitoring, and the daily management burden the disease requires. For a young child, it can also mean being older and more capable of participating in their own care when the diagnosis eventually arrives. Screening makes this kind of early intervention possible, which is why awareness of the pre-symptomatic stages has become increasingly important for families with a history of type 1 diabetes.